Takeda UK has announced UK Medicines and Healthcare products Regulatory Agency (MHRA) approval of fruquintinib (Fruzaqla) as a treatment for adults with metastatic colorectal cancer (CRC) after other therapies have failed. Fruquintinib functions by inhibiting the formation of new blood vessels in tumours – essential for providing nutrients and oxygen – thus slowing cancer growth. The gold standard of business intelligence.
The approval was based on results from two pivotal studies, FRESCO-2 and FRESCO, which assessed the therapy. FRESCO-2 enrolled 691 adult patients with previously treated metastatic CRC. It included subjects with disease progression following or not tolerant to chemotherapy, biologics and trifluridine/tipiracil (TAS-102) and/or regorafenib.
Data showed that patients on Fruzaqla had a median survival of 7.4 months versus 4.8 months for the placebo group.
The Fruzaqla group experienced a median of 3.7 months without disease progression, compared to 1.8 months for those on placebo.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form The FRESCO trial, conducted exclusively in China with 416 adult subjects, reported that tho.